Skip to main content

sofosbuvir/velpatasvir (Epclusa®)

 

Status: Recommended

Sofosbuvir/velpatasvir (Epclusa®) is recommended as an option for use within NHS Wales for the treatment of chronic hepatitis C virus (HCV) infection in patients from 3 years of age to < 18 years of age, in line with the National Institute of Health and Care Excellence recommendation for the use of sofosbuvir/velpatasvir for treating chronic HCV infection in adults (TA430).

 Final Recommendation: sofosbuvir velpatasvir (Epclusa) 4573 (PDF, 382Kb)

Medicine details

Medicine name sofosbuvir/velpatasvir (Epclusa®)
Formulation 150 mg/37.5 mg coated granules, 200 mg/50 mg coated granules
Reference number 4573
Indication

Treatment of chronic hepatitis C virus (HCV) infection in patients from 3 years of age to less than 18 years of age

Company Gilead Sciences Ltd
BNF chapter Infections
Submission type Licence extension for paediatric use
Status Recommended
Advice number 0123
AWMSG meeting date 08/02/2023
Date of issue 15/02/2023
Follow AWTTC: